Skip to main content
GeoVax Labs, Inc. logo

GeoVax Labs, Inc. — Investor Relations & Filings

Ticker · GOVX ISIN · US3736786068 LEI · 549300KXK8Z4UZ4J7S86 US Professional, scientific and technical activities
Filings indexed 1,031 across all filing types
Latest filing 2025-11-26 Regulatory Filings
Country US United States of America
Listing US GOVX

About GeoVax Labs, Inc.

https://www.geovax.com/

GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms. The company's lead oncology program is Gedeptin®, a therapy for advanced head and neck cancers which has completed enrollment in a Phase 1/2 clinical trial. Its primary infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine being evaluated in Phase 2 clinical trials for high-risk, immunocompromised populations and as a heterologous booster. GeoVax's development pipeline also includes research programs for preventive vaccines against Mpox, smallpox, hemorrhagic fever viruses such as Ebola and Marburg, malaria, and Zika virus, alongside therapies for various solid tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2025-11-26 English
FORM 8-K
Regulatory Filings
2025-11-13 English
FORM 424B3
Prospectus
2025-11-13 English
FORM 424B3
Prospectus
2025-11-13 English
FORM 424B3
Prospectus
2025-11-13 English
FORM 424B3
Prospectus
2025-11-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.